NL-Den Bosch-JBZ
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT07223814 | |
| Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT05791409 | |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | B-cell neoplasm, Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, diffuse large B-cell lymphoma, heart disorder, heart failure, histiocytosis, immune system disorder, immunoproliferative disorder, injury, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, radiation injury | Recruiting | Phase 3 | 2026-09-23 | NCT06220032 | |
| A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-09-23 | NCT06014489 | |
| The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL | diffuse large B-cell lymphoma, non-Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-09-23 | NCT03463057 | |
| A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-09-22 | NCT03839771 | |
| REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 2 | 2026-09-21 | NCT04523428 | |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-09-02 | NCT06652438 | |
| Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2025-08-19 | NCT07075016 | |
| A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2024-12-17 | NCT04027309 | |
| Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients | AML/MDS | Active, not recruiting | Phase 2 | 2024-09-19 | NCT04097470 | |
| FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2024-08-19 | NCT06187441 | |
| DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2024-02-14 | NCT03620578 | |
| Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 2 | 2023-11-01 | NCT03673826 |